In summary, this study demonstrated that GZFL combined with DNG is more clinically effective in the treatment of EMs than DNG alone, and the potential theoretical mechanism by which it functions may involve modulation of hormone receptors and inflammation. The gene discussed is NR4A1; the disease is eosinophilia-myalgia syndrome.